Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy
NCT00726544 · Archemix Corp. · PHASE2 · terminated · last registry update 2009-11-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Enrollment into study was slower than expected.” | – | Registry record, Archemix Corp. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against VWF within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2010-03-03Also stopped (terminated): Bio Products Laboratory, Optivate (NCT00404300)
- 2010-03-03Also stopped (terminated): Bio Products Laboratory, Optivate (NCT00387192)
- 2010-02-10Also stopped (terminated): Archemix Corp., ARC1779 Injection + Placebo (normal saline) (NCT00742612)
- 2009-08-21Also stopped (withdrawn): Archemix Corp., ARC1779 + ARC1779 (NCT00694785)
- 2009-07-17Phase 3 first posted: CSL Behring, Biostate® + Biostate® (NCT00941616)
- 2009-01-09Also stopped (terminated): Archemix Corp., a drug against VWF (NCT00507338)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision